Please select the option that best describes you:
Topics:
Internal Medicine • Hematology • Neurology • Cardiology • Neuro-critical care • Vascular Neurology • General Neurology • Anticoagulation • Cardiac Electrophysiology • Circulation Journal Club
Do you consider bleeding risk in elderly, frail patients with atrial fibrillation to be similar for all NOACs?
In FRAIL-AF, participants were switched from VKA to dabigatran, rivaroxaban, apixaban, and edoxaban.
Answer from: at Community Practice
I believe that apixaban carries a lower risk of bleeding, with particular reference to GI bleed, when compared to rivaroxaban and dabigatran. This is true in the population of AF patients at large and most probably in frail patients as well.
Sign in or Register to read more
Answer from: at Academic Institution
The prior evidence would suggest that not all NOACS have the same bleeding risk. More specifically, Apixaban appears to have a lower risk of GI bleeding than Rivaroxaban. While this is based on observational analyses, and head-to-head trials of non-generic medications are hard to come by, I have enc...